I've sent an email to Greg Collier today...
I note that Terumo returned the rights for Propofol TPM injection to Avecho in October, 2019.
More recently, in the Chairman's Address, April 2020 it is reported that Avecho has subsequently moved forward to develop a 2nd generation Propofol TPM injectable.
The question I ask, is Avecho able to update the market how far along toxicology testing has progressed for this latest generation and when we would likely know, or not, if this testing supports longer term infusion?
2nd generation Propofol TPM injectable
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $1.58K | 472.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 60811132 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 33319922 | 20 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.4¢ |
Change
0.001 ( 16.7 %) |
||||
| Open | High | Low | Volume | ||
| 0.3¢ | 0.4¢ | 0.3¢ | 12003495 | ||
| Last updated 15.59pm 28/05/2024 ? | |||||
| AVE (ASX) Chart |